Role of Micronized Progesterone Versus Dydrogestron in Patients with Threatened Abortion

Rukhsana shaikh; Ayesha Jalbani; Shaista Lashari; Saeed-un-Nisa Sangi; Sumera Brohi; Quratulain shaikh

Rukhsana shaikh Consultant Gynaecologist & Obstetrician, Sheikh Zayed Women CMC Hospital Larkana
Ayesha Jalbani Consultant Gynaecologist & Obstetrician, Sheikh Zayed Women CMC Hospital Larkana
Shaista Lashari Senior Registrar in Gynae & Obst, Sheikh Zayed Women Hospital, Shaheed Mohtarma Benazir Bhutto Medical University Larkana
Saeed-un-Nisa Sangi Consultant Gynaecologist & Obstetrician, Sheikh Zayed Women CMC Hospital Larkana
Sumera Brohi Consultant Gynaecologist & Obstetrician, Sheikh Zayed Women CMC Hospital Larkana
Quratulain shaikh Consultant Gynaecologist & Obstetrician, Sheikh Zayed Women CMC Hospital Larkana

Keywords: Vaginal bleeding, Micronised Progesterone, Dydrogesterone

Abstract

Objective: To compare the efficacy of Micronized Progesterone vs Dydrogestron in patients with Threatened Abortion.

Setting and Duration of Study:

Methodology: This Randomized Controlled Trial study was conducted in outpatient department of Obstetrics and Gynaecology, Sheikh Zayed Women CMC Hospital Larkana, from January 2021 to September 2021. A total of 140 patients with age ranging from 20 to 45 years, presented with signs of threatened abortion before 20 weeks of gestation, having single intrauterine pregnancy based on ultrasound findings, presenting with vaginal bleeding were enrolled for the study. Demographic information including patient number, name, age, gestational age, body mass index, history of previous miscarriages, duration of bleeding, extent of bleeding at presentation and after treatment and side effects (nausea, vomiting, giddiness, bloating, diarrhea and headache). The miscarriage rate until 24 weeks of gestation was noted. All this information was recorded on a predesigned performa.

Results: The mean age of Micronized Progesterone group (28.65 ± 5.2) was similar to Dydrogestron group (29.35 ± 4.85). There was no significant (P-value > 0.05) difference between both groups on the basis of gestational age (7.52 ± 3.2 vs. 7.25 ± 3.4), body mass index (23.4 ± 3.6 vs. 22.9 ± 3.2) and previous miscarriage rate (68.57% vs. 61.43%). Post treatment extent of bleeding was almost comparable in both groups. The rate of drowsiness (61.43% vs. 31.43%) and giddiness (22.86% vs. 8.57%) was significantly (P-value < 0.05) higher in Micronized Progesterone group as compared to Dydrogestron group. The side effects of nausea and abdominal bloating were similar in both treatment groups.

Conclusions: Micronised Progesterone and Dydrogesterone treatments showed similar efficacy in the treatment of threatened miscarriage. Although the rate of side effects was significantly higher in women treated with Micronised Progesterone.